BiotechTube

Fostamatinib disodium + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Warm Antibody Autoimmune Hemolytic Anemia

Conditions

Warm Antibody Autoimmune Hemolytic Anemia

Trial Timeline

Apr 24, 2019 → Apr 11, 2022

NCT ID
NCT03764618

About Fostamatinib disodium + Placebo

Fostamatinib disodium + Placebo is a phase 3 stage product being developed by Rigel Pharmaceuticals for Warm Antibody Autoimmune Hemolytic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03764618. Target conditions include Warm Antibody Autoimmune Hemolytic Anemia.

What happened to similar drugs?

0 of 5 similar drugs in Warm Antibody Autoimmune Hemolytic Anemia were approved

Approved (0) Terminated (1) Active (4)
🔄Ianalumab + PlaceboNovartisPhase 3
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
❌parsaclisinib + placeboIncytePhase 3
🔄Obexelimab + ObexelimabZenas BioPharmaPhase 3
🔄Fostamatinib disodiumRigel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT03764618Phase 3Completed
NCT02076412Phase 3Completed
NCT02076399Phase 3Completed

Competing Products

12 competing products in Warm Antibody Autoimmune Hemolytic Anemia

See all competitors
ProductCompanyStageHype Score
Ianalumab + PlaceboNovartisPhase 3
44
rituximab (Mabthera®) + PlaceboRochePhase 3
40
rilzabrutinibSanofiPhase 2
39
Isatuximab SAR650984SanofiPhase 2
27
parsaclisinib + placeboIncytePhase 3
29
RVT-1401 680 mg/weekly + RVT-1401 340 mg/weeklyImmunovantPhase 2
24
HMPL-523(300mg PO QD) + PlaceboHUTCHMEDPhase 2/3
36
APL-2Apellis PharmaceuticalsPhase 2
29
Obexelimab + ObexelimabZenas BioPharmaPhase 3
38
ANX005AnnexonPhase 2
29
Fostamatinib 150 mg bidRigel PharmaceuticalsPhase 2
29
Fostamatinib disodiumRigel PharmaceuticalsPhase 3
41